I could be wrong but we are being assessed against the current standard of care. That is currently other TAVR devices. So I assume we would publish our results against the thousands of existing published results for existing on market devices. (these well documented results make up the current standard of care.)
I don’t think we actually implant other companies devices in this trial.
Not advice and DYOR.
Ann: Annual Report to shareholders, page-9
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.81 |
Change
-0.170(0.90%) |
Mkt cap ! $365.2M | |||
| Open | High | Low | Value | Volume |
| $19.00 | $19.00 | $18.52 | $39.57K | 2.119K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 208 | $18.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.00 | 210 | 1 |
View Market Depth
| Last trade - 11.36am 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$18.52 |
Change
-0.170 ( 2.01 %) |
||||
| Open | High | Low | Volume | ||
| $18.52 | $18.52 | $18.52 | 14 | ||
| Last updated 10.49am 30/05/2024 ? | |||||
| AVR (ASX) Chart |